Stock comparison
Genmab A/S
Royalty Pharma
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
RPRX
Royalty Pharma
Market cap
$23.44B
Sector
Healthcare
Overall winner
Royalty Pharma RPRX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | RPRX | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 66C | RPRX |
| Benjamin Graham | 64C | 84A | RPRX |
| Philip Fisher | 48D | 65C | RPRX |
| Peter Lynch | 25F | 60C | RPRX |
| Joel Greenblatt | 76B | 40D | GMAB |
| Charlie Munger | 68C | 68D | Tie |
| Terry Smith | 71C | 58D | GMAB |
Side-by-side metrics
| Metric | GMAB | RPRX |
|---|---|---|
| Market cap | $16.5B | $23.44B |
| P/E (TTM) | 6.2x | 27.6x |
| EV/EBIT | 12.0x | 19.9x |
| ROIC (TTM) | 43.78% | 8.43% |
| Gross margin | 93.88% | 99.95% |
| Net margin | 18.23% | 33.91% |
| Revenue CAGR 5y | -18.45% | 0.96% |
| EPS CAGR 5y | -23.48% | 11.83% |
| Debt / Equity | 0.1x | 1.3x |
| Dividend yield | 0.0% | 1.72% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Debt / Equity0.1xvs 1.3x+94%
- ROIC (TTM)43.78%vs 8.43%+81%
- P/E (TTM)6.2xvs 27.6x+78%
- EV/EBIT12.0xvs 19.9x+40%
RPRX leads on
- EPS CAGR 5y11.83%vs -23.48%+150%
- Revenue CAGR 5y0.96%vs -18.45%+105%
- Dividend yield1.72%vs 0.0%+100%
- Net margin33.91%vs 18.23%+46%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.